Your session is about to expire
← Back to Search
Budesonide for Engraftment Syndrome After Stem Cell Transplant
Study Summary
This trial tests if a drug can reduce fever after stem cell transplants, to help patients recover better.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 222 Patients • NCT02055352Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 18 and 80 years old and have been diagnosed with a blood cancer.I am eligible for a stem cell transplant according to the BMT program's criteria.I have had a stem cell transplant for a cancer that is not related to blood.
- Group 1: nothing
- Group 2: Budesonide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial open to those over the age of fifty?
"As stipulated by the study's regulations, people who are 18 or over can be enrolled and those under 80 may participate."
What is the current enrollment of this experiment?
"Affirmative. The relevant information hosted on clinicaltrials.gov indicates that this experiment is currently seeking participants; the study was initially posted on November 9th 2022 and later amended with a minor edit to its details. Approximatively 110 people need to be recruited from one location for this trial."
Has Budesonide received its stamp of approval from the FDA?
"Due to the presence of clinical data indicating efficacy and numerous reports validating safety, our team at Power have assigned Budesonide a score of 3 on their scale."
Is enrollment for this research endeavor still available?
"Affirmative. Clinicaltrials.gov records show that this research is actively searching for participants, with an initial posting date of November 9th 2022 and a most recent update on the same day. A total of 110 subjects need to be enrolled from one medical facility."
Is my eligibility sufficient to partake in this clinical research?
"This trial seeks to enroll 110 people, between the ages of 18 and 80 who have a particular syndrome. In order for participants to qualify, they must meet two conditions: (1) be diagnosed with a hematological cancer; and (2) fulfill Bone Marrow Transplant Program criteria established for managing said malignancies."
Share this study with friends
Copy Link
Messenger